Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature. (October 2015)

• Record Type: Journal Article
• Authors: Casciaro, Rosaria; Naselli, Aldo; Cresta, Federico; Ros, Mirco; Castagnola, Elio; Minicucci, Laura
• Is Part Of: Journal of chemotherapy. Volume 27:Number 5(2015:Oct.)
• Page Start: 307
• Page End: 311
• Publication Date: 2015-10
• Subjects: Amphotericin B, -- Cystic fibrosis, -- Antifungal therapy, -- Aspergillosis, -- Azole antifungals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947814Y.0000000194
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : Objectives: To review the data available in literature about nebulized amphotericin B (AMB) in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) and to report our experience in the use of this drug, with a particular therapeutic scheme. Case Report: We used nebulized liposomal amphotericin B (L-AMB) in a patient affected by CF, complicated by ABPA. The previous combined treatment with oral steroids and azoles had no respiratory benefit and caused relevant side effects. Amphotericin B has always been well tolerated and permitted a slight steroid tapering. We also observed benefits in pulmonary function and laboratory tests. Conclusions: Few data are available in literature about the use of nebulized AMB in CF and there are no RCTs evaluating antifungals in CF-ABPA. In our opinion, the reported case suggests that nebulized L-AMB could represent a possible strategy in ABPA management in CF patients.